Besides, the high frequency of L1CAM expression in high‐risk ECs indicates a potential role as a therapeutic target against which human monoclonal antibody (MAb) approaches have been explored in various types of cancer.28, 29, 30. The gene discussed is L1CAM; the disease is cancer.